Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Senti Biosciences Inc
Healthcare
P/NCAV
0.71x
Ticker
SNTI
Exchange
NASDAQ
Country
United States
Close
0.3 $
Mkt Cap
13.3M $
EV
-22.5M $
NCAV Burn Rate
62.0%
Current Ratio
5.62
Debt/Equity
0.0
EV/REV
-8.79x
EV/EBIT
0.2x
EV/FCF
0.6x
Dilution
0.4% p.A
Total Net Income
-225.6M $
Cheapness
99.0%
Senti Biosciences, Inc. is a clinical-stage biotechnology company. It is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. It is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average